Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000449538
Ethics application status
Approved
Date submitted
12/02/2024
Date registered
12/04/2024
Date last updated
21/04/2025
Date data sharing statement initially provided
12/04/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis
Scientific title
A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis
Secondary ID [1] 311523 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mental Health 332872 0
Incurable Cancer 333050 0
Adjustment Disorder 333051 0
Condition category
Condition code
Mental Health 329592 329592 0 0
Other mental health disorders
Cancer 329727 329727 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This Phase 2b study is a double-blind, 1:1:1 randomized, study to assess the efficacy, safety and tolerability of 25 mg, 10 mg and 1 mg [low-dose comparator] PEX010 in participants with adjustment disorder (AjD) following an incurable cancer diagnosis.
The study will consist of a combination of clinic visits and telehealth visits and will involve the following study sequence:
A screening visit (approximately 3 hours): within Day-28 to -1
Visit at the clinic for continued eligibility and baseline assessments: Day -1 (1-2 hours)
PAP cycle: Day 1 to Day 28
In Clinic Visits: Day 1, 13, 14, 15, 84
Telehealth appointments: Day 7, Day 21, Day 28, Day 56, Day 168 and Day 253

(Psychiatrist/Psychologist/Psychotherapist): Preparatory therapy session: Day 1, Day 7, Day 13 (approximately 1 hour) - Participants must complete three preparation sessions with the therapist in the two weeks prior to the dosing session. Two of these sessions can be completed remotely via telehealth and have flexible timing, The remote sessions can be conducted at any time between Day 1 and Day 13, provided there is at least one day between each session. One preparation session must be done in person in the dosing room, ideally during a face to face appointment at Clinic on Day 13. Participants will attend three preparatory sessions (one virtual (Day 7) telehealth and two in-person (Day 1, Day 13)) in the two weeks prior to being treated with psilocybin. The therapist will support the participant to establish intentions and goals, to be prepared for a range of potential effects of the psilocybin and have sufficient information to approach the intervention with an open mind.

Face to face appointment at clinic to be conducted with a suitably trained therapist
(Psychiatrist/Psychologist/Psychotherapist).

Drug administration: Day 14 (approximately 8 hours). Participants will receive a single administration of PEX010 (capsule) under medical supervision on Day 14. Participants will be supported through the acute effects of the psilocybin by a suitably qualified therapist who will be present throughout the drug-assisted session. For the majority of the session the participant will be encouraged to wear a headset with a playlist and a blindfold to encourage introspection. A mouth check will be conducted to ensure compliance with dosing.

Integration Session: Integration sessions will be conducted on Day 15 and Day 21 (approximately 1 hour). The Integration session on Day 15 will be a Face-to-face appointment at clinic to be conducted with a suitably trained therapist (Psychiatrist/Psychologist/Psychotherapist). An integration session conducted via telehealth with a suitably trained therapist will be conducted remotely in the two weeks following the dosing session. The integration sessions allow participants to process the experience of their drug-assisted session, consolidate changes into their perspective, reinforce insights from the therapy, and revisit issues that arose during the session. During the integration sessions, the therapist will facilitate the participant to reflect on their experiences of the psilocybin intervention, with the aim of translating their experiences into practical and accessible objectives.

Follow-up: Day 84 (week 12) (Clinic visit, approximately 1 hour) Eligible non-responders at Week 12 will be offered a second PAP cycle (at 25 mg PEX010 dose level). For eligible participants the second PAP cycle will include all activities from Day 13 onwards until Day 253. A maximum of 2 PAP cycles may be administered. To be conducted with a suitably trained therapist (Psychiatrist/Psychologist/Psychotherapist).
Final study follow-up

Follow-up Telehealth appointments (Approximately 1 hour): Day 168 (Month 3), Day 253 (Month 6) (calculated from the 12-week visit after the final PAP). To be conducted with a suitably trained therapist (Psychiatrist/Psychologist/Psychotherapist)
Session attendance checklists will be incorporated throughout the duration of the study to ensure compliance with all components of the intervention.
Intervention code [1] 327976 0
Treatment: Drugs
Comparator / control treatment
Low-dose comparator – 1mg PEX010
Oral capsule administration of low-dose comparator (1mg PEX010) with mouth checks to confirm compliance. The control group will also receive psychedelic assisted psychotherapy.
Control group
Dose comparison

Outcomes
Primary outcome [1] 337370 0
To assess the change in anxiety severity in participants with AjD due to an incurable cancer diagnosis, as measured by HAM-A.
Timepoint [1] 337370 0
Comparison between treatment groups in the change from baseline in the HAM-A total score at Week 10 after a single PAP cycle.
Primary outcome [2] 337372 0
To assess the safety and tolerability of a single dose of PEX010 (25 mg, 10 mg and 1 mg [low-dose comparator]) in people with AjD with an incurable cancer diagnosis.
Timepoint [2] 337372 0
Assessment of Day 14 (dosing day) vital signs (pre-dose and prior to discharge).
Primary outcome [3] 337534 0
To assess the safety and tolerability of a single dose of PEX010 (25 mg, 10 mg and 1mg [low-dose comparator]) in people with AjD with an incurable cancer diagnosis
Timepoint [3] 337534 0
Assessment of suicidality using the S-STS (baseline, Day 13, Day 15, 4, 6, and 10-weeks and 3- months post-final cycle.
Secondary outcome [1] 431598 0
To assess the change in anxiety severity after receiving PAP in participants with AjD and an incurable cancer diagnosis
Timepoint [1] 431598 0
Comparison between treatment groups after a single PAP cycle of change from baseline in the HAM-A total score at Day 15, Week 4, Week 6, and 10 weeks post randomization and 3 months post final cycle
Secondary outcome [2] 431600 0
To assess the change in depression severity after receiving PAP in participants with AjD and an incurable cancer diagnosis.
Timepoint [2] 431600 0
Comparison between treatment groups after a single PAP cycle: Change from baseline in HAM-D at Day 15, 4-, 6- and 10 weeks post randomization and 3 months post-final cycle
Secondary outcome [3] 431601 0
To assess the efficacy of PAP in changing severity of AjD for participants with an incurable cancer diagnosis.
Timepoint [3] 431601 0
Comparison between treatment groups after a single PAP cycle:* Change from baseline in the ADNM-20 20 at Day 15, 4-, 6- and 10 weeks post- randomization and 3 months post-final cycle * Percentage of participants who achieve ‘remission’ of AjD defined by ADNM-20 score of 47.5 or less and Distress Thermometer Score <4 at Week 10 after 1 cycle. * Percentage of participants who achieve ‘remission’ of AjD defined by ADNM-20 score of 47.5 or less and Distress Thermometer Score<4 at Week 10 after a 2nd cycle. * Change from baseline in the Demoralization Scale at Day 15 and 4-, 6- and 10 weeks post- randomization.
Secondary outcome [4] 432242 0
To assess the change in depression severity after receiving PAP in participants with AjD and an incurable cancer diagnosis
Timepoint [4] 432242 0
Comparison between treatment groups after a single PAP cycle of change from baseline in the HAM-A total score 20 at Day 15, 4-, 6- and 10 weeks post randomization and 3 months post-final cycle

Eligibility
Key inclusion criteria
To be eligible for study entry participants must satisfy all of the following criteria:
1. Screening AjD diagnosis (ICD-11), as defined by an ADNM-20 score = 47.5 , a score
of = 4 on the Distress Thermometer
2. Screening HAM-A Score =18 (moderate anxiety).
3. Adults aged 18 to 80 years (inclusive) at screening.
4. Diagnosed with incurable cancer (exempting those cancers listed in the exclusion
criteria) and a minimum life-expectancy of 12 months in the opinion of the treating
physician, with performance status of 0-2 on the Eastern Cooperative Oncology Group
(ECOG) scale.
5. Agrees not to commence any new psychiatric medications or psychotherapies from
Screening to Week 10.
6. Able to communicate well and follow study procedures, judged as sufficiently
competent with the English language by the investigator, able to build adequate rapport
with study staff.
7. Judged to be of low suicide risk based on Sheehan-Suicide Tracking Scale (S-STS) and
the opinion of a research team psychiatrist.
8. Be medically suitable in the opinion of the investigator as determined by screening for
medical problems via a personal interview, a medical questionnaire, a physical
examination, an electrocardiogram (ECG), and blood tests.
9. Have access to a device that is compatible to use the digital technology, i.e smart-phone
device tablet.
10. Agree not to take any sedating medicationsfor a minimum of 12 hours before the dosing
session including benzodiazepines, zopiclone, eszopiclone, zaleplon and zolpidem.
Medications for cancer-related pain are permitted.
11. Must be willing and able to refrain from smoking throughout the duration of the dosing
session. Nicotine replacement therapies may be permitted with the agreement of the
medical monitor.
12. Agree that for 1week before the psilocybin dosing session, participants will refrain from
taking any illegal drugs or non-prescription medication (including cannabis, or CBD or
THC containing products), nutritional supplement, or herbal supplement except when
approved by the study investigators.
13. Participants taking any other medication that is not explicitly detailed as an excluded
medication will be discussed with the investigator and medical monitor as appropriate.
Decisions on inclusion will be based on clinical judgement and with sufficient
justification provided
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Psychiatric Exclusion Criteria:
1. Current major depressive disorder (MDD) (or within 12 months of Screening),
current or past diagnosis of schizophrenia, psychotic disorder, unless this was
substance-induced or resulting from a medical condition (e.g. lupus or malaria etc.),
bipolar disorder I and II, delusional disorder, paranoid personality disorder,
schizoaffective disorder, borderline personality disorder, anti-social personality
disorder or judged to be incompatible with establishment of rapport or safe exposure
to psilocybin, as assessed through medical history and the Mini Neuropsychiatric
Inventory (MINI 7.0.2) by any specialist psychiatrist or registered medical
professional under the authorized delegation of a specialist psychiatrist.
2. First-degree relative with a diagnosed psychotic disorder.
3. Scores from the screening psychiatrist (or registered medical professional under
the authorized delegation of a specialist psychiatrist) and baseline (S-STS) indicate
that the participant is of clinically significantrisk ofsuicide. A decision will be formed
based on S-STS scores and used in combination with other clinically significant data
at screening. Sites should refer to the medical monitor if required.
4. Has attempted suicide in the 12 months preceding the screening visit.
5. Current (< 1 year) alcohol or drug abuse asidentified as moderate or severe during screening in accordance with Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) criteria, using the MINI 7.0.2, not able or willing to abstain from alcohol
consumption in the period 12 hours prior to the dosing session.
6. Any other reason that might prevent a participant from engaging in therapeutic
preparation and integration sessions.
7. Previous use of psychedelics within 12 months preceding screening.
Medical Exclusion Criteria:
1. Diagnosed with brain metastases, glioblastoma, phaeochromocytoma, bowel
obstruction or intestinal failure, active carcinoid syndrome, uncontrolled
hypercalcaemia, or uncontrolled diabetes mellitus or insipidus.
2. Currently taking or planning to take any of the following: any typical or atypical
antipsychotic and monoamine-oxidase inhibitors. Participants with prior use of these
medications must be willing to discontinue their use for at least 2 weeks prior to the
baseline visit and to Day 28.
3. Currently taking or planning to take any anticonvulsant or mood stabilizer,
including carbamazepine, lithium, phenytoin, and valproate. Participants with prior
use of these medications must be willing to discontinue their use for at least 1 week
prior to the baseline visit and to Day 28.
4. Participants who have taken selective serotonin reuptake inhibitor/serotoninnorepinephrine reuptake inhibitor (selective and norepinephrine reuptake inhibitor
[SNRI] and selective serotonin reuptake inhibitor [SSRI]) within the last 3 months
and/or who are planning to initiate them before Day 70 of their study participation.
5. Any form of fungal allergy.
6. Positive pregnancy test at screening, women who are breastfeeding or of
childbearing potential who are unwilling or unable to use an effective form of
contraception (or abstinence) for the study period and for 1 month post PEX010 dose
will be excluded. Women will be required to conduct a serum pregnancy test at the
in-person screening visit and urine test prior to dosing session. Male participants who
do not agree to use contraception for the study period and for 90 days post PEX010
dose to mitigate the risk of pregnancy will also be excluded. Note: Refer to Section
5.3.2.1 for further details about contraception.
7. A diagnosis of epilepsy or at significant risk of seizures based on medical history.
8. Cardiovascular conditions including stroke and/or myocardial infarction (less than
one year before providing informed consent), uncontrolled hypertension (blood
pressure > 140/90 mmHg) or clinically significant arrhythmia at screening. Results
are exempt if they are a direct result of the participant’s cancer diagnosis and do not
present a risk to administration of psilocybin, following discretion of the investigator.
9. Anyone who, at screening, has clinically significant findings on physical
examination, including resting vital signs (heart rate below 40 or above 120 bpm,
blood pressure below 90/60 or above 140/90), ECG (QTcF > 450 msec for males
and >470 for females), and positive alcohol breath test. Note: Testing for any outof-range values may be repeated at the discretion of the Investigator.
10. Liver dysfunction at screening as defined by ALT/AST >1.5 times the upper limit of
normal or upper reference range. Results are exempt if they are a direct result of the
participant’s cancer diagnosis and do not present a risk to the administration of
psilocybin, following discretion of the investigator.
11. Renal Function: estimated glomerular filtration rate <60 mL/min (calculated
using Chronic Kidney Disease Epidemiology Collaboration) unless this is a direct
result of the cancer diagnosis and does not present a risk to the administration of
psilocybin, following the discretion of the investigator.
12. Any clinically significant laboratory abnormality(s) that in the opinion of the
investigator would present a risk to the administration of psilocybin.
13. Any clinically significant renal, pulmonary, gastrointestinal, hepatic, or other
illness that could affect the interpretation of results or be a potential health risk for
the person if they were to be included in the study. Results are exempt if they are a direct result of the participant’s cancer diagnosis and do not present a risk to
administration of psilocybin, following discretion of the investigator.
14. Below 18 or above 32 kg/m2 Body Mass Index (BMI) score at Screening.
15. Anyone with organic brain injury or diagnosed with any cognitive impairment.
16. Positive urine drug test for non-prescribed psychoactive substances at the Dosing
sessionvisit. Positive urine drug test for psychoactive substances at the in-person
screening should be referred to the medical monitor. Note: Testing may be repeated
once at the discretion of the Investigator.
17. Anyone on a research study of an investigational drug or who has been on a
clinical trial within 3 months of enrollment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed Opaque Envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
16/12/2024
Actual
Date of last participant enrolment
Anticipated
31/12/2026
Actual
Date of last data collection
Anticipated
31/03/2027
Actual
Sample size
Target
87
Accrual to date
0
Final
Recruitment in Australia
Recruitment state(s)
WA,VIC

Funding & Sponsors
Funding source category [1] 315814 0
Commercial sector/Industry
Name [1] 315814 0
Psyence Australia Pty Ltd
Country [1] 315814 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Psyence Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 318085 0
None
Name [1] 318085 0
Address [1] 318085 0
Country [1] 318085 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 314672 0
Bellberry Human Research Ethics Committee B
Ethics committee address [1] 314672 0
Ethics committee country [1] 314672 0
Australia
Date submitted for ethics approval [1] 314672 0
05/03/2024
Approval date [1] 314672 0
05/03/2024
Ethics approval number [1] 314672 0
2023-05-605

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 132358 0
Dr Arul Sivanesan
Address 132358 0
Vitalis Research Centre: 15, 456 St. Kilda Road, Melbourne VIC 3004
Country 132358 0
Australia
Phone 132358 0
+613 9125 3604
Fax 132358 0
Email 132358 0
[email protected]
Contact person for public queries
Name 132359 0
Dr Arul Sivanesan
Address 132359 0
Vitalis Research Centre: 15, 456 St. Kilda Road, Melbourne VIC 3004
Country 132359 0
Australia
Phone 132359 0
+61 404 253 343
Fax 132359 0
Email 132359 0
[email protected]
Contact person for scientific queries
Name 132360 0
Michelle Tusler
Address 132360 0
iNGENu CRO: Unit 22, 456 St Kilda Road, Melbourne, VIC 3004
Country 132360 0
Australia
Phone 132360 0
+61 390500654
Fax 132360 0
Email 132360 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.